Brigatinib for Schwannoma – pro
There are pre-clinical studies, specifically one phase 2 platform study with neurofibromatosis that showed a 23% response in the meningioma and schwannoma group, adn one abstract of radiographic responses . It also references having treated several patients in their institution in this way. Unfortunatley, this is insufficient to establish medical necessity.
Scott R. Plotkin, et al, Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors. N Engl J Med 2024;390:2284-2294
Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in a Heavily Pretreated Cohort of Patients with NF2-Related Schwannomatosis. https://www.esmo.org/oncology-news/treatment-with-brigatinib-results-in-radiographic-responses-and-clinical-benefit-in-a-heavily-pretreated-cohort-of-patients-with-nf2-related-schwannomatosis